Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.31 |
| ▸ | IL1B | P01584 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620727 | 0.83 | BTK (0.41) | MITFCES2CES1 | |
| SCHEMBL25250387 | 0.83 | BTK (0.41) | MITFCES2CES1 | |
| SCHEMBL849602 | 0.83 | BTK (0.41) | MITFCES2CES1 | |
| SCHEMBL30726182 | 0.82 | KDM4E (0.38) | MITFCES2CES1NR1H2NR1H3 | |
| SCHEMBL15541922 | 0.82 | KDM4E (0.38) | MITFCES2CES1NR1H2NR1H3 | |
| SCHEMBL3126066 | 0.82 | KDM4E (0.38) | MITFCES2CES1NR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL15542195 | 0.80 | KDM4E (0.37) | MITFNR1H2NR1H3 | |
| SCHEMBL4021239 | 0.80 | OAT (0.31) | — | |
| SCHEMBL15443019 | 0.77 | SMN1; SMN2 (0.40) | MITF | |
| SCHEMBL25757922 | 0.77 | MITF (0.33) | MITFNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009100403-A1 | SUBSTITUTED ARYL PYRIMIDINONES | NEUROGEN CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100403-A1 | SUBSTITUTED ARYL PYRIMIDINONES | NEUROGEN CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008156607-A1 | SUBSTITUTED PYRIMIDINONES | NEUROGEN CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156607-A1 | SUBSTITUTED PYRIMIDINONES | NEUROGEN CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7087605-B2 | 5-Ethyl-imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| EP-1397363-B1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2004-12-16 | — | — | US | disclosed |
| EP-1397363-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098880-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | EPX, TPMT, IL5 | MITF 1873/4885CES2 1980/4885CES1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.